Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity

Vivek Dipak Gandhi; Nami Shrestha Palikhe; Harissios Vliagoftis

doi:10.3389/fmed.2022.954990

Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity

Front Med (Lausanne). 2022 Jul 29:9:954990. doi: 10.3389/fmed.2022.954990. eCollection 2022.

Authors

Vivek Dipak Gandhi^{1

2

3}, Nami Shrestha Palikhe^{1

2}, Harissios Vliagoftis^{1

2}

Affiliations

¹ Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
² Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.
³ School of Health Sciences and Technology, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India.

Abstract

PAR₂, a receptor activated by serine proteases, has primarily pro-inflammatory roles in the airways and may play a role in asthma pathogenesis. PAR₂ exerts its effects in the lungs through activation of a variety of airway cells, but also activation of circulating immune cells. There is evidence that PAR₂ expression increases in asthma and other inflammatory diseases, although the regulation of PAR₂ expression is not fully understood. Here we review the available literature on the potential role of PAR₂ in asthma pathogenesis and propose a model of PAR₂-mediated development of allergic sensitization. We also propose, based on our previous work, that PAR₂ expression on peripheral blood monocyte subsets has the potential to serve as a biomarker of asthma severity and/or control.

Keywords: PAR-2; allergic disease; asthma; biomarker; severity.

Publication types

Review